ArticleLancet (London, England)2013
Evaluation of regorafenib in colorectal cancer and GIST.
Article in Lancet (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- VEGF signaling: Role in angiogenesis and beyond.Biochimica et biophysica acta. Reviews on cancer · 2024Review
- Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.AAPS PharmSciTech · 2024Review
- Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema.Experimental & molecular medicine · 2023Article
- Advances in 3D Vascularized Tumor-on-a-Chip Technology.Advances in experimental medicine and biology · 2022Article
- Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment.Nature communications · 2021Article
- Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.International journal of molecular sciences · 2020Article
- Article
- IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.Oncotarget · 2017Article
- Management of regorafenib-related toxicities: a review.Therapeutic advances in gastroenterology · 2015Review
- KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.Gastroenterology · 2015Article
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.International journal of genomics · 2015Review
- Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Journal of gastrointestinal oncology · 2013Article
- Critical appraisal of the use of regorafenib in the management of colorectal cancer.Cancer management and research · 2013Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23177516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.